|1.||Holland, William S: 1 article (07/2014)|
|2.||Mack, Philip C: 1 article (07/2014)|
|3.||Chinn, Danielle C: 1 article (07/2014)|
|4.||Pession, Andrea: 1 article (01/2014)|
|5.||Bertaina, Alice: 1 article (01/2014)|
|6.||Melchionda, Fraia: 1 article (01/2014)|
|7.||Chiarini, Francesca: 1 article (01/2014)|
|8.||Evangelisti, Cecilia: 1 article (01/2014)|
|9.||Evangelisti, Camilla: 1 article (01/2014)|
|10.||Bressanin, Daniela: 1 article (01/2014)|
|1.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/01/2014 - "Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies."
07/01/2014 - "We sought to assess the preclinical efficacy of MK-5108 in a panel of non-small-cell lung cancer cell lines as a single agent and in combination with cisplatin and docetaxel. "
01/01/2010 - "MK-5108 is currently tested in clinical trials and offers a new therapeutic approach to combat human cancers as a single agent or in combination with existing taxane therapies."
06/15/2012 - "Gavage of an orthotopic ULMS model with MK-5108 at 30 or 60 mg/kg decreased the number and size of tumor implants compared with sham-fed controls. "
01/01/2010 - "MK-5108 also induced phosphorylated Histone H3 in skin and xenograft tumor tissues in a nude rat xenograft model. "
07/01/2014 - "MK-5108 induced G2/M accumulation, polyploidy, and apoptosis (increased sub-G1/PARP cleavage). "
07/01/2011 - "The intracellular changes associated with MK-5108 treatment are: (1) polyploidy and cell cycle arrest; (2) inhibition of NFκB activity; (3) decreased cytokine production; and (4) nuclear accumulation of IκBα. "
|4.||Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
|4.||aurora kinase (aurora A kinase)
|7.||salicylhydroxamic acid (SHAM)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)